What is Lavior?
Lavior is dedicated to providing advanced solutions for diabetic wound and skin conditions, drawing upon 15 years of dedicated research and medical expertise. The company's innovative product line is formulated using the therapeutic properties of the Inula Viscosa AGS RIED species, offering natural and effective treatments for chronic dermatological issues. Lavior's mission is to mitigate the risk of amputations and enhance overall skin health, with its scientifically-backed botanical healing solutions gaining global trust. Following a recent rebranding, Lavior continues its commitment to science-powered natural healing.
How much funding has Lavior raised?
Lavior has raised a total of $15K across 3 funding rounds:
Multiple Rounds
$15K
Debt (2024): $5K, investors not publicly disclosed
Debt (2024): $5K led by First Internet Bancorp
Debt (2024): $5K, investors not publicly disclosed
Key Investors in Lavior
First Internet Bancorp
First Internet Bancorp is a financial institution that likely provides debt financing or other forms of capital to support company growth and operational needs.
What's next for Lavior?
With the recent capital injection, Lavior is poised for strategic expansion and further development of its innovative treatment portfolio. The Series A/B growth stage funding indicates a focus on scaling operations, enhancing market reach, and potentially investing in further research and clinical trials to solidify its position in the diabetic care market. This investment will likely fuel initiatives aimed at broadening product accessibility and reinforcing its commitment to preventing amputations through advanced botanical therapies.
See full Lavior company page
